Latest news
Ractigen Reaches Key Phase II Milestone for RAG-17 in SOD1-ALS Program - tipranks.comtipranks.com · Thu, 06 Aug 2026 12:30:52 GMTRactigen Therapeutics Announces Completion of Enrollment and First Dosing in Phase II Clinical Trial of RAG-17 for SOD1-ALS - The Manila TimesThe Manila Times · Thu, 06 Aug 2026 11:56:14 GMTFDA Clears IND for RAG-1C saRNA candidate targeting proliferative vitreoretinopathy - Ophthalmology Times EuropeOphthalmology Times Europe · Mon, 03 Aug 2026 19:02:58 GMTIND open for Ractigen’s RAG-1C in proliferative vitreoretinopathy - bioworld.combioworld.com · Mon, 03 Aug 2026 13:00:00 GMTFDA Clears Ractigen IND Application for Novel saRNA Candidate in Proliferative Vitreoretinopathy - Contract PharmaContract Pharma · Fri, 31 Jul 2026 14:54:44 GMTRactigen Wins Dual U.S.–China IND Clearances for First-in-Class saRNA Eye Therapy RAG-1C - tipranks.comtipranks.com · Fri, 31 Jul 2026 11:29:51 GMTRactigen Therapeutics Announces U.S. FDA IND Clearance for First-in-Class saRNA Candidate RAG-1C to Treat Proliferative Vitreoretinopathy - The Manila TimesThe Manila Times · Fri, 31 Jul 2026 11:26:59 GMTChinese saRNA pioneer Ractigen raises fresh cash - The Pharma LetterThe Pharma Letter · Thu, 30 Jul 2026 13:37:39 GMT